Lugano, Switzerland – The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, today announced that Professor Christoph Zielinski will be the Editor-in-Chief of ESMO Open, ESMO’s new, peer reviewed, open access, online only journal. ESMO Open is dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research. The first articles will be published in January 2016.
“Being appointed Editor-in-Chief of ESMO Open is a lifetime dream come true,” said Zielinski. “I have played an active role in ESMO ever since becoming a member in 1996. In January 2015, I was appointed Chair of the ESMO Fellowship and Award Committee, while I have been a member of the Executive Board since 2013. I was in the Scientific Committee and Local Officer for the ESMO 2012 Congress in Vienna and I will similarly serve as Local Officer for the European Cancer Congress 2015 in Vienna. In my new role as Editor-in-Chief of ESMO Open my goal is to publish significant science quickly in an open access format.”
Zielinski, 63, is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University in Vienna, Austria. He has been President of the Central European Cooperative Oncology Group since 1999.
Zielinski’s clinical speciality is medical oncology. His research focuses on clinical trials in breast cancer, lung cancer, personalised medicine and immuno-oncology. He has published more than 600 papers. Zielinski studied at the Medical University Vienna and the Cancer Research Centre at Tufts University in Boston, Massachusetts, USA.
“My priority as Editor-in Chief will be to combine an even greater visibility for ESMO, with critical reviews and comments on an open access online basis, on top of original papers, of course,” said Zielinski. “The editorial team will seek scientific manuscripts from across the field of oncology, be it experimental or clinical. We want exceptional clinical challenges in reviews, original papers on cutting-edge technologies and scientific insights, ESMO news and views, and lively editorials - everything that makes a journal modern, exciting, and worth reading.”
ESMO Open will operate a fast submission and review process with continuous publication online to ensure that timely, up-to-date research is available worldwide and adheres to a rigorous and transparent peer-review process.
Zielinski concluded: “With the explosion of knowledge in oncology, an open-access online journal was desperately needed. We will publish important papers quickly and be a crucial addition to ESMO’s flagship journal Annals of Oncology.”
Notes to Editors
About ESMO
ESMO is the leading European professional organisation for medical oncology. Comprising more than 11,000 oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
Founded in 1975, ESMO has European roots and a global reach: we welcome oncology professionals from around the world. We are a home for all oncology stakeholders, connecting professionals with diverse expertise and experience. Our educational and information resources support an integrated, multi-professional approach to cancer treatment. We seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.
About ESMO Open
ESMO Open is the online journal of ESMO. It is an online only, peer reviewed, open access oncology journal dedicated to publishing high quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.
About BMJ
BMJ is a healthcare knowledge provider that aims to advance healthcare worldwide by sharing knowledge and expertise to improve experiences, outcomes and value. A full list of BMJ products and services is available here: bmj.com